Comparative Biosciences continues to evolve with niche and specialty preclinical, IND enabling GLP or non-GLP otic and auditory toxicology, efficacy, pharmacokinetics/pharmacodynamics in relevant animal species.
CBI will be attending the ARVO annual meeting in Baltimore, MD this year. Please contact our business development team to set up a meeting about your upcoming research needs!
As the largest organ in the human body, skin plays a vital role in overall health and well-being. With over 20 years of experience, Comparative Biosciences has an arsenal of innovative and validated pharmacological models for dermatological therapeutics.
Clinical indications caused by neonatal hyperoxygenation such as bronchopulmonary fibrosis and retinopathy of prematurity have created an unmet medical need for therapeutic treatments. Comparative Biosciences has multiple robust and validated methods, ready to advance your therapeutic development.
CBI will be attending SOT for our 20th year! Stop by booth #1932 and speak to our expert team about your upcoming preclinical research needs! Look for our poster at the show! Our very own Dr. Laine Ooi will be presenting a poster for our hyperoxia-induced pulmonary dysplasia model.
Whatever your ocular study needs, Comparative Biosciences has the answer. With over 20 years of proficiency in the preclinical sphere, we have experience and expertise that you can count on.
CBI was founded in 1996 by three partners in Santa Clara, CA. We conducted our first GLP study in 1997 and later expanded to our state-of-the-art purpose built facilities in Sunnyvale, CA. Our initial focus involved specialty services, and we continue this dedication 20 years later. This month we are celebrating our 20th anniversary.
CBI has been helping our Sponsors with developing ocular therapies for 20 years. CBI’s experience and our Sponsors’ innovations are leading to new therapies and clinical trials to advance treatment of ocular diseases.
Comparative Biosciences is your resource for preclinical Ocular Gene Therapy and Regenerative Medicine Studies.
Focusing on Oncology Studies
CBI has evaluated many potential anti-cancer compounds, our in-house expertise allows us to optimally design studies that provide critical pre-clinical efficacy data. Our custom study plans meet your research needs and prepare you for regulatory submission.
CBI is proud to announce expanded capabilities in imaging to support discovery, exploratory, pharmacology and toxicology studies. We are able to provide the following new imaging capabilities to support your in-vivo preclinical studies: Dermal Fibrosis, LDI (Laser Doppler Instrument), OCT Optical Coherence Tomography), IVS Imaging and PET Scanning, MRI, Digital Radiology, CT and MicroCT
Visit us at the NIH research festival exhibit in Bethesda, MD, booth #1013. We are also continuing with grant support, from letters of support to collaboration and good faith pricing. Let’s partner together.
Optical Coherence Tomography, or “OCT” is a technique for obtaining sub-surface images of translucent or opaque materials at a resolution equivalent to a low-power microscope. It reveals or detects subtle changes, particularly in the eye, that are not visible by other means such as with slit lamp biomicroscopy or funduscopy.
Watch the OCT Demonstration Video
Ocular Studies | Antibacterial Research and Consulting | OCT Studies
In situ hybridization (ISH) is a technique used to detect and localize the precesnce or absence of a specific genetic sequence in tissue using a probe with a complementary polynucleotide sequence.
Comparative Biosciences, Inc. offers both fluprescent (FISH) and chromogenic (CISH) is situ hybridization assays.
In Situ Hybridization Studies | Histopathology Studies
Xenografts of human tumor tissue into laboratory animal species provide a more accurate model of tour growth and activity administered drugs than in vitro studies. Comparative Biosciences, Inc. offers in vivo xenograft services to conduct drug development for oncology, playing a major role in development of new anti-cancer medicines and therapies.
Xenograft Studies | Histological | Antibacterial Research & Consulting
Atherosclerosis is present in nearly 52% of americans and represents a huge unmet medical need. It occurs when fat, cholesterol and other substances build up in the walls of arteries and form hard structures called plaques. For companies investigating this disease and its associated symptoms, Comparative Biosciences, Inc. offers efficacy models and studies.C
Contact us for more information on Atherosclerosis studies.
Pharmacology | Atherosclerosis Studies | Antibacterial Research & Consulting
Congratulations to all of our clients and colleagues who have launched successful INDS this past year! Comparative Biosciences, Inc. leader in stem cell pharmacology and GLP Toxicology congratulates our friends and colleagues on their IND successes in 2014, Viacyte, Xeris Pharmaceuticals, Celdara Medical and UCSD.
Contact us to discuss your complex IND needs.ust completed a long term ocular implant, and a long term dermal toxicity as well as numerous burn studies.
Pharmacology | Stem Cell Research | Antibacterial Research & Consulting
Mini-pigs are being used for toxicology and for a wide variety of pharmacology modeling. Comparative Biosciences, Inc. just completed a long term ocular implant, and a long term dermal toxicity as well as numerous burn studies.
Optical Coherence Tomography (OCT) | Thermal Burn Modeling | Antibacterial Research & Consulting
CBI Dermal OCT Scanning is used in our biomedical research, pharmacology and toxicology, including GLP studies. Our system enables new research opportunities. Applications include Ocular, Skin Models, Xenografts, Rodent Ears, and Tissue Engineering.
Optical Coherence Tomography (OCT) | Stem Cell Research | Antibacterial Research & Consulting
CBI provides contract histology, immunohistochemistry, and pathology services to the biopharmaceutical industry. Whether preparing a single biopsy, a complex histomorphometry study or a complete carcinogenicity study, CBI offers high quality slide preparation, pathological evaluation, and reporting in a timely and cost effective manner. Histopathology is clearly one of the most important tools for assessment of drug efficacy and activity.
Histology Laboratory Capabilities | Immunohistochemistry | Pathology
CBI is the industry leader in conducting difficult and complicated IND enabling and research studies with Stem Cells and Stem-Cell Device combination studies. We have conducted these complex studies in multiple species and for durations exceeding 1.5 years.
Stem Cell Research | Pharmacology | Antibacterial Research and Consulting
CBI is offering for the month of September/October MAA Ocular INFLAMMATION modeling in rats that recapitulates the human disease of Anterior Uveitis.
CBI offers both exploratory proof-of-concept toxicity and tolerability studies and complete preclinical studies. We are also offering OCT intraocular assessments.
CBI is developing the models to test the therapeutics that could accelerate the wound healing process. Learn more about our thermal burn modeling services and are Dermal Pharmacology and Efficacy Studies.
CBI provides a wrap-up from ARVO and is now offering OCT intraocular assessments as well as IOP, ERG and angiography.
CBI provides exploratory/proof-of-concept, GLP toxicology, pharmacokinetics, in vivo animal models, pharmacology, and histopathalogy/immunohistochemistry related to the eye. We are now also offering Optical Coherence Tomography (OCT) for research and toxicology studies. We will be exhibiting at The Association for Research in Vision and Ophthalmology (ARVO) next week, May 4-8, 2014 at booth #338, please stop by.
CBI offers a complete program of preclinical research services to support a range of toxicology including: Acute, Subacute and Chronic Toxicity Studies-IND Enabling, Discovery and early Toxicology, Investigative, Ocular, Otic and Dermal Toxicology, Stem Cell Toxicology and many more. We also have a variety of special equipment and capabilities to supplement our regular toxicology.
CBI’s unique experience in preclinical contract otic studies and state-of-the-art facilities, we have the skill and expertise to accelerate new ear drugs from discover y through the drug development process to regulatory submission.
CBI offers a range of infection modeling for the purposes of identification of novel anti-infective agents, particularly MRSA, vancomycin-resistant staph, and gram positive organisms.
Immune-mediated FX-1A-induced glomerular nephritis in rats is an excellent translational model of immune mediated membranous glomerular nephritis in humans.
This research concerned the neurotoxic effects of dexmedetomidine in fetal cynomolgus monkey brains. In this study, the effects of dexmedetomidine anesthesia was compared to ketamine anesthesia.
Optical Coherence Tomography
Otic Toxicology Studies
Thermal Burn Modeling
FDA New Guidance on Biosimilars
Models of MS: EAE Models in Mice
2011 SOT Convention
Is the Venture Funding Drought Finally Over?
Space Available for Rent at CBI
Tissue Cross-Reactivity Studies
CT Scanning at CBI